Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants

American Journal of Pathology

Volumn 167, Issue 5, 2005, Pages 1389-1403

  Miller, Daniel W ^a,b   Vosseler, Silvia ^a   Mirancea, Nicolae ^a   Hicklin, Daniel J ^d   Bohlen, Peter ^d   Völcker, Hans E ^b   Holz, Frank G ^b,c   Fusenig, Norbert E ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE B; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; PROTEINASE; TENASCIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CANCER CELL CULTURE; CANCER REGRESSION; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL STRUCTURE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INVASIVE CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; ZYMOGRAPHY;

EID: 27544495515     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)61226-6     Document Type: Article

References (54)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31
2. Jain RK, Carmeliet PF: Vessels of death or life. Sci Am 2001, 285:38-45
3. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795-803
4. Alitalo K, Carmeliet P: Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002, 1:219-227
5. Fusenig NE, Skobe M, Vosseler S, Hansen M, Lederle W, Airola K, Tomakidi P, Stark HJ, Steinbauer H, Mirancea N, Boukamp P, Breitkreutz D: Tissue models to study tumor-stroma interactions. Proteases and Their Inhibitors in Cancer Metastasis. Edited by Muschel RJFJ. Dordrecht, Kluwer Academic Publishers, 2002, pp 205-223
6. Mueller MM, Fusenig NE: Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839-849
7. Fusenig NE, Boukamp P: Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog 1998, 23:144-158
8. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE: Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997, 3:1222-1227
9. Mueller MM, Fusenig NE: Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 2002, 70:486-497
10. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE: Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988, 106:761-771
11. Boukamp P, Stanbridge EJ, Foo DY, Cerutti PA, Fusenig NE: c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res 1990, 50:2840-2847
12. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998, 4:923-928
13. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noel A: The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001, 152:777-784
14. Skobe M, Fusenig NE: Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci USA 1998, 95:1050-1055
15. Bleuel K, Popp S, Fusenig NE, Stanbridge EJ, Boukamp P: Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc Natl Acad Sci USA 1999, 96:2065-2070
16. Javaherian A, Vaceariello M, Fusenig NE, Garlick JA: Normal keratinocytes suppress early stages of neoplastic progression in stratified epithelium. Cancer Res 1998, 58:2200-2208
17. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159-165
18. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-395
19. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Bohlen P: Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/ KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998, 17:155-161
20. Mueller MM, Peter W, Mappes M, Huelsen A, Steinbauer H, Boukamp P, Vaccariello M, Garlick J, Fusenig NE: Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol 2001, 159:1567-1579
21. Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE: Angiogenesis inhibition by VEGFR-2 blockade reduces stromal MMP expression, normalizes stromal tissue and reverts tumor phenotype. Cancer Res 2005, 65:1294-1305
22. Chiquet-Ehrismann R, Chiquet M: Tenascins: regulation and putative functions during pathological stress. J Pathol 2003, 200:488-499
23. Moorman AF, De Boer PA, Vermeulen JL, Lamers WH: Practical aspects of radio-isotopic in situ hybridization on RNA. Histochem J 1993, 25:251-266
24. Borchers AH, Steinbauer H, Schafer BS, Kramer M, Bowden GT, Fusenig NE: Fibroblast-directed expression and localization of 92-kDa type IV collagenase along the tumor-stroma interface in an in vitro three-dimensional model of human squamous cell carcinoma. Mol Carcinog 1997, 19:258-266
25. Airola K, Fusenig NE: Differential stromal regulation of MMP-1 expression in benign and malignant keratinocytes. J Invest Dermatol 2001, 116:85-92
26. Werb Z, Vu TH, Rinkenberger JL, Coussens LM: Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS 1999, 107:11-18
27. Coussens LM, Tinkle CL, Hanahan D, Werb Z: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490
28. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ: Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002, 94:1134-1142
29. Masson V, de la Ballina LR, Munaut C, Wielockx B, Jost M, Maillard C, Blacher S, Bajou K, Itoh T, Itohara S, Werb Z, Libert C, Foidart JM, Noel A: Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J 2005, 19:234-236
30. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039
31. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000, 105:R15-R24
32. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999, 59:5209-5218
33. Barsky SH, Siegal GP, Jannotta F, Liotta LA: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 1983, 49:140-147
34. Hagedorn HG, Bachmeier BE, Nerlich AG: Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas. Int J Oncol 2001, 18:669-681
35. Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176
36. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000, 18:1135-1149
37. Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999, 103:1237-1241
38. Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, Uehira M: Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 1999, 17:177-181
39. Wagner S, Fueller T, Hummel V, Rieckmann P, Tonn JC: Influence of VEGF-R2 inhibition on MMP secretion and motility of microvascular human cerebral endothelial cells (HCEC). J Neurooncol 2003, 62:221-231
40. Quaranta V: Cell migration through extracellular matrix: membrane-type metalloproteinases make the way. J Cell Biol 2000, 149:1167-1170
41. Streuli CH, Schmidhauser C, Bailey N, Yurchenco P, Skubitz AP, Roskelley C, Bissell MJ: Laminin mediates tissue-specific gene expression in mammary epithelia. J Cell Biol 1995, 129:591-603
42. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999, 59:5002-5011
43. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW: The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 2002, 70:537-546
44. Tlsty TD: Stromal cells can contribute oncogenic signals. Semin Cancer Biol 2001, 11:97-104
45. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257
46. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 2002, 99:11399-11404
47. Feng D, Nagy JA, Hipp J, Dvorak HF, Dvorak AM: Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med 1996, 183:1981-1986
48. Jones FS, Jones PL: The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000, 218:235-259
49. Kiessling F, Farhan N, Lichy MP, Vosseler S, Heilmann M, Krix M, Bohlen P, Miller DW, Mueller MM, Semmler W, Fusenig NE, Delorme S: Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 2004, 6:213-223
50. Brown EB, Campbell RB, Tsuzuki Y, Xu L, Carmeliet P, Fukumura D, Jain RK: In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 2001, 7:864-868
51. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165:35-52
52. Lobov IB, Brooks PC, Lang RA: Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002, 99:11205-11210
53. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998
54. Ramsauer M, D'Amore PA: Getting Tie(2)d up in angiogenesis. J Clin Invest 2002, 110:1615-1617